JACC:经皮冠脉介入治疗支架内完全闭塞的疗效观察

2017-05-08 xiangting MedSci原创

IS-CTO患者的手术成功率高且与新生CTO相似。然而,IS-CTO在随访中与MACE(由TVR驱动)独立相关。

这项研究旨在探讨经皮冠脉介入治疗(PCI)支架内慢性完全闭塞(IS-CTO)的长期预后和不良事件的预测因素。IS-CTO PCI被认为与次优成功率相关。

研究人员对3个专科中心进行CTO PCI的患者进行多中心登记。患者分为IS-CTO和新生CTO。主要终点(主要不良心脏事件[MACE])包括随访中的心源性死亡、心肌梗死和缺血驱动的靶血管血运重建(TVR)。用Cox回归法寻找MACE的独立预测因子。

共包括899名患者(n=111 IS-CTO,n=788新生CTO)。2组间基线临床血管造影特征类似。总体平均J-CTO(日本慢性完全闭塞)评分为1.88±1.24,平均进展期CTO(前瞻性全球慢性完全闭塞干预登记-CTO)评分为1.04±0.88。在59%的IS-CTO和48.1%的新生CTO患者中使用了顺行导丝递增(P=0.08)。两组手术成功率均达86.5%(P= 0.99)。在中位随访471(四分位数范围:354至872)天之后,MACE在IS-CTO与新生CTO(P= 0.07)中分别为20.8%和13.9%(P= 0.07),受TVR影响(16.7%vs.9.4%;P=0.03)。IS-CTO是MACE的独立预测因子(风险比:2.16;95%置信区间:1.18-3.95;P= 0.01),连同之前的手术血运重建和肾功能,CTO PCI提示急性冠脉综合征、病变血管数目和PROGRESS-CTO评分。

IS-CTO患者的手术成功率高且与新生CTO相似。然而,IS-CTO在随访中与MACE(由TVR驱动)独立相关。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1853629, encodeId=290b185362922, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Fri Nov 17 21:06:00 CST 2017, time=2017-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325367, encodeId=3811132536e59, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed May 10 07:06:00 CST 2017, time=2017-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443538, encodeId=63c1144353825, content=<a href='/topic/show?id=1ed0309444e' target=_blank style='color:#2F92EE;'>#冠脉介入治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30944, encryptionId=1ed0309444e, topicName=冠脉介入治疗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/8u3mGRpJpSHpz8GnN2RDHUVc5Vm6yUoQhqesfhJoyZjndetgiaQV6z9uzia2U2DkZ8ZWXqJBZTHXxib22b7nngyhw/132, createdBy=f44f5082140, createdName=12498ebem20暂无昵称, createdTime=Wed May 10 07:06:00 CST 2017, time=2017-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460445, encodeId=4045146044550, content=<a href='/topic/show?id=f2cde83988e' target=_blank style='color:#2F92EE;'>#经皮冠脉介入治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78398, encryptionId=f2cde83988e, topicName=经皮冠脉介入治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555a6326698, createdName=zhanglin3081, createdTime=Wed May 10 07:06:00 CST 2017, time=2017-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1596076, encodeId=4d6b15960e6d7, content=<a href='/topic/show?id=f2c4e8397a7' target=_blank style='color:#2F92EE;'>#经皮冠脉介入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78397, encryptionId=f2c4e8397a7, topicName=经皮冠脉介入)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=298b18326857, createdName=shock_melon, createdTime=Wed May 10 07:06:00 CST 2017, time=2017-05-10, status=1, ipAttribution=)]
    2017-11-17 hbwxf
  2. [GetPortalCommentsPageByObjectIdResponse(id=1853629, encodeId=290b185362922, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Fri Nov 17 21:06:00 CST 2017, time=2017-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325367, encodeId=3811132536e59, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed May 10 07:06:00 CST 2017, time=2017-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443538, encodeId=63c1144353825, content=<a href='/topic/show?id=1ed0309444e' target=_blank style='color:#2F92EE;'>#冠脉介入治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30944, encryptionId=1ed0309444e, topicName=冠脉介入治疗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/8u3mGRpJpSHpz8GnN2RDHUVc5Vm6yUoQhqesfhJoyZjndetgiaQV6z9uzia2U2DkZ8ZWXqJBZTHXxib22b7nngyhw/132, createdBy=f44f5082140, createdName=12498ebem20暂无昵称, createdTime=Wed May 10 07:06:00 CST 2017, time=2017-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460445, encodeId=4045146044550, content=<a href='/topic/show?id=f2cde83988e' target=_blank style='color:#2F92EE;'>#经皮冠脉介入治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78398, encryptionId=f2cde83988e, topicName=经皮冠脉介入治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555a6326698, createdName=zhanglin3081, createdTime=Wed May 10 07:06:00 CST 2017, time=2017-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1596076, encodeId=4d6b15960e6d7, content=<a href='/topic/show?id=f2c4e8397a7' target=_blank style='color:#2F92EE;'>#经皮冠脉介入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78397, encryptionId=f2c4e8397a7, topicName=经皮冠脉介入)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=298b18326857, createdName=shock_melon, createdTime=Wed May 10 07:06:00 CST 2017, time=2017-05-10, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1853629, encodeId=290b185362922, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Fri Nov 17 21:06:00 CST 2017, time=2017-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325367, encodeId=3811132536e59, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed May 10 07:06:00 CST 2017, time=2017-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443538, encodeId=63c1144353825, content=<a href='/topic/show?id=1ed0309444e' target=_blank style='color:#2F92EE;'>#冠脉介入治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30944, encryptionId=1ed0309444e, topicName=冠脉介入治疗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/8u3mGRpJpSHpz8GnN2RDHUVc5Vm6yUoQhqesfhJoyZjndetgiaQV6z9uzia2U2DkZ8ZWXqJBZTHXxib22b7nngyhw/132, createdBy=f44f5082140, createdName=12498ebem20暂无昵称, createdTime=Wed May 10 07:06:00 CST 2017, time=2017-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460445, encodeId=4045146044550, content=<a href='/topic/show?id=f2cde83988e' target=_blank style='color:#2F92EE;'>#经皮冠脉介入治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78398, encryptionId=f2cde83988e, topicName=经皮冠脉介入治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555a6326698, createdName=zhanglin3081, createdTime=Wed May 10 07:06:00 CST 2017, time=2017-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1596076, encodeId=4d6b15960e6d7, content=<a href='/topic/show?id=f2c4e8397a7' target=_blank style='color:#2F92EE;'>#经皮冠脉介入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78397, encryptionId=f2c4e8397a7, topicName=经皮冠脉介入)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=298b18326857, createdName=shock_melon, createdTime=Wed May 10 07:06:00 CST 2017, time=2017-05-10, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1853629, encodeId=290b185362922, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Fri Nov 17 21:06:00 CST 2017, time=2017-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325367, encodeId=3811132536e59, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed May 10 07:06:00 CST 2017, time=2017-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443538, encodeId=63c1144353825, content=<a href='/topic/show?id=1ed0309444e' target=_blank style='color:#2F92EE;'>#冠脉介入治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30944, encryptionId=1ed0309444e, topicName=冠脉介入治疗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/8u3mGRpJpSHpz8GnN2RDHUVc5Vm6yUoQhqesfhJoyZjndetgiaQV6z9uzia2U2DkZ8ZWXqJBZTHXxib22b7nngyhw/132, createdBy=f44f5082140, createdName=12498ebem20暂无昵称, createdTime=Wed May 10 07:06:00 CST 2017, time=2017-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460445, encodeId=4045146044550, content=<a href='/topic/show?id=f2cde83988e' target=_blank style='color:#2F92EE;'>#经皮冠脉介入治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78398, encryptionId=f2cde83988e, topicName=经皮冠脉介入治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555a6326698, createdName=zhanglin3081, createdTime=Wed May 10 07:06:00 CST 2017, time=2017-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1596076, encodeId=4d6b15960e6d7, content=<a href='/topic/show?id=f2c4e8397a7' target=_blank style='color:#2F92EE;'>#经皮冠脉介入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78397, encryptionId=f2c4e8397a7, topicName=经皮冠脉介入)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=298b18326857, createdName=shock_melon, createdTime=Wed May 10 07:06:00 CST 2017, time=2017-05-10, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1853629, encodeId=290b185362922, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Fri Nov 17 21:06:00 CST 2017, time=2017-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325367, encodeId=3811132536e59, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed May 10 07:06:00 CST 2017, time=2017-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443538, encodeId=63c1144353825, content=<a href='/topic/show?id=1ed0309444e' target=_blank style='color:#2F92EE;'>#冠脉介入治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30944, encryptionId=1ed0309444e, topicName=冠脉介入治疗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/8u3mGRpJpSHpz8GnN2RDHUVc5Vm6yUoQhqesfhJoyZjndetgiaQV6z9uzia2U2DkZ8ZWXqJBZTHXxib22b7nngyhw/132, createdBy=f44f5082140, createdName=12498ebem20暂无昵称, createdTime=Wed May 10 07:06:00 CST 2017, time=2017-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460445, encodeId=4045146044550, content=<a href='/topic/show?id=f2cde83988e' target=_blank style='color:#2F92EE;'>#经皮冠脉介入治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78398, encryptionId=f2cde83988e, topicName=经皮冠脉介入治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555a6326698, createdName=zhanglin3081, createdTime=Wed May 10 07:06:00 CST 2017, time=2017-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1596076, encodeId=4d6b15960e6d7, content=<a href='/topic/show?id=f2c4e8397a7' target=_blank style='color:#2F92EE;'>#经皮冠脉介入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78397, encryptionId=f2c4e8397a7, topicName=经皮冠脉介入)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=298b18326857, createdName=shock_melon, createdTime=Wed May 10 07:06:00 CST 2017, time=2017-05-10, status=1, ipAttribution=)]

相关资讯

NEJM:常规PCI是选择生物可吸收支架还是金属支架?

这项在接受PCI患者中进行的试验的初步报告中,接受可吸收支架和金属支架的患者之间在靶血管衰竭的发生率上没有显著差异。通过2年的随访发现生物可吸收支架比金属支架出现支架内血栓的发生率较高。

NEJM:瞬时无波型比率或分数流量储备在PCI中的应用情况!

在主要不良心脏事件1年风险方面,IFR引导的冠状动脉血运重建并不劣于FFR指导的血运重建。IFR比FFR的不良手术操作的症状和体征发生率要低,手术时间也要短。

南方会2017:Henry H. Ting: 我们支架做了很多,效果如何?

经皮冠状动脉介入治疗(PCI)的质量改善是目前国内外心血管领域面临的重大挑战。昨日上午,哥伦比亚大学Henry H. Ting 教授在南方会上针对这个话题介绍了他的观点和经验。他认为,就目前美国真实世界的情况来看, PCI 质量改善有五大机会。仅半数择期PCI 适宜Ting 教授指出,评估PCI 质量的第一步是要根据适用标准(Appropriate Use Criteria) 评估PCI 是否适宜

NEJM:血流储备分数指导的多支血管成形术在心肌梗死中的运用!

对于已经在梗死相关动脉进行PCI的STEMI和多支血管病变患者,在急性期FFR指导的非梗死相关动脉完全性血运重建会发生复合心血管终点风险,但低于在那些只处理梗死相关动脉患者的风险。

Circ-Cardiovasc Inte:2型糖尿病患者PCI后血糖控制状况及长期临床结局!

经皮冠状动脉介入治疗后2年测得HbA1c<7与MACCE发生率降低相关。该研究的数据表明经皮冠状动脉介入术后2年HbA1c水平升高可以识别不良事件风险增加的人群,尤其是重复血运重建的患者。

CIRC J:血清白蛋白和C反应蛋白对经皮冠状动脉介入治疗患者的远期结局的作用

之前研究报道炎症和营养不良与动脉粥样硬化,尤其是伴随慢性肾脏病的患者密切相关。本研究探讨了经皮冠状动脉介入术(PCI)后血清白蛋白和C反应蛋白(CRP)对临床疗效的综合影响。本研究纳入2000年至2011年间2,164例冠状动脉疾病患者首次进行PCI治疗,术前行血清白蛋白和hs-CRP水平检测得到相关数据。根据患者血清白蛋白和CRP水平(分别为4.1 g / dL和0.10 mg / dL)将其分